Open AccessSecukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study
Author(s) -
Pavelka Karel,
Kivitz Alan J.,
Dokoupilova Eva,
Blanco Ricardo,
Maradiaga Marco,
Tahir Hasan,
Wang Yi,
Porter Brian O.,
Stefanska Anna,
Richards Hanno B.,
Rohrer Susanne
Publication year - 2020
Publication title -
acr open rheumatology
Language(s) - English
Resource type - Journals
ISSN - 2578-5745
DOI - 10.1002/acr2.11102
Subject(s) - secukinumab , ankylosing spondylitis , medicine , placebo , spondylitis , randomized controlled trial , gastroenterology , disease , psoriatic arthritis , pathology , alternative medicine
Objective Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis ( AS ), with response rates sustained for up to 5 years. Here, we report end‐of‐study 3‐year efficacy and safety results of secukinumab 150 and 300 mg from the MEASURE 3 study. Methods A total of 226 patients was randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous (s.c.) secukinumab 300/150 mg every 4 weeks or a matched placebo. At week 16, placebo patients were re‐randomized to s.c. secukinumab 300/150 mg. Analysis at week 156 included patients initially randomized to secukinumab and those who switched from placebo to secukinumab at week 16 (any secukinumab 300/150 mg). Outcome measures at week 156 included Assessment of Spondyloarthritis International Society ( ASAS ) 20/40, Bath Ankylosing Spondylitis Disease Activity Index, ASAS partial remission ( PR ), ASAS 5/6, and Ankylosing Spondylitis Disease Activity Score–C‐reactive protein inactive disease. Results The retention rates from weeks 16 to 156 were 80.5% and 80.9% in secukinumab 300 and 150 mg, respectively. ASAS 20/40 response rates at week 156 were 75.0%/56.5% and 68.2%/47.7% for secukinumab 300 and 150 mg, respectively. At week 156, response rates on more stringent clinical end points (eg, ASAS 40, ASAS ‐ PR ) were higher with the 300‐mg dose, particularly in tumor necrosis factor ( TNF )–inadequate responder ( IR ) patients. No new safety findings were observed. Conclusion Secukinumab (300 and 150 mg) provided sustained improvements through 3 years in the signs and symptoms of active AS . Improvements with secukinumab 300 mg were numerically higher compared with the 150‐mg dose for some higher hurdle end points and in TNF ‐ IR patients. The safety profile of secukinumab was consistent with previous reports.